Characterization of T‐DM1‐resistant breast cancer cells

The development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T‐DM1 (trastuzumab‐emtansine) is an antibody‐drug conjugate used for the treatment of HER2‐positive breast cancer combining the FDA approved mAb (monoclonal antibody) trastuzumab an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauveur, Juliette, Conilh, Louise, Beaumel, Sabine, Chettab, Kamel, Jordheim, Lars‐Petter, Matera, Eva‐Laure, Dumontet, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314699/
https://www.ncbi.nlm.nih.gov/pubmed/32583565
http://dx.doi.org/10.1002/prp2.617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314699/
https://www.ncbi.nlm.nih.gov/pubmed/32583565
http://dx.doi.org/10.1002/prp2.617

Ejemplares similares